NASDAQ:AGLE - Aeglea Bio Therapeutics Stock Price, Forecast & News

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.12. View Aeglea Bio Therapeutics' Earnings History.

Aeglea Bio Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Aeglea Bio Therapeutics.

2 brokerages have issued twelve-month price targets for Aeglea Bio Therapeutics' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Aeglea Bio Therapeutics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 114.1% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics.

Headlines about AGLE stock have trended negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of -2.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Aeglea Bio Therapeutics.

Aeglea Bio Therapeutics saw a drop in short interest in December. As of December 13th, there was short interest totalling 197,500 shares, a drop of 21.8% from the November 28th total of 252,500 shares. Based on an average trading volume of 52,700 shares, the days-to-cover ratio is currently 3.7 days. Currently, 0.8% of the shares of the company are short sold. View Aeglea Bio Therapeutics' Current Options Chain.

Some companies that are related to Aeglea Bio Therapeutics include Radius Health (RDUS), Achillion Pharmaceuticals (ACHN), Phathom Pharmaceuticals (PHAT), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), ZIOPHARM Oncology (ZIOP), Applied Therapeutics (APLT), Aprea Therapeutics (APRE), Dova Pharmaceuticals (DOVA), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA), Provention Bio (PRVB), Collegium Pharmaceutical (COLL), CannTrust (CNTTF) and Stoke Therapeutics (STOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea Bio Therapeutics investors own include ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Iovance Biotherapeutics (IOVA), ADMA Biologics (ADMA), Arcturus Therapeutics (ARCT), Amicus Therapeutics (FOLD), Kura Oncology (KURA), Ocular Therapeutix (OCUL), Opko Health (OPK) and Spectrum Pharmaceuticals (SPPI).

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea Bio Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Comprehensive Portfolio Management LLC (0.84%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn and Bioventures Ltd Novartis. View Institutional Ownership Trends for Aeglea Bio Therapeutics.

AGLE stock was sold by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC. View Insider Buying and Selling for Aeglea Bio Therapeutics.

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGLE stock can currently be purchased for approximately $7.94.

Aeglea Bio Therapeutics has a market capitalization of $230.18 million and generates $3.89 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe.View Additional Information About Aeglea Bio Therapeutics.

The official website for Aeglea Bio Therapeutics is http://www.aegleabio.com/.

Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]